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Abstract
 
Toll–IL-1–resistance (TIR) domain–containing adaptor-inducing IFN-
 
  
 
(TRIF)–related adaptor
molecule (TRAM) is the fourth TIR domain–containing adaptor protein to be described that
participates in Toll receptor signaling. Like TRIF, TRAM activates interferon regulatory factor
(IRF)-3, IRF-7, and NF-
 
 
 
B-dependent signaling pathways. Toll-like receptor (TLR)3 and
4 activate these pathways to induce IFN-
 
 
 
/
 
 
 
, regulated on activation, normal T cell expressed
and secreted (RANTES), and 
 
 
 
 interferon–inducible protein 10 (IP-10) expression indepen-
dently of the adaptor protein myeloid differentiation factor 88 (MyD88). Dominant negative
and siRNA studies performed here demonstrate that TRIF functions downstream of both the
TLR3 (dsRNA) and TLR4 (LPS) signaling pathways, whereas the function of TRAM is restricted
to the TLR4 pathway. TRAM interacts with TRIF, MyD88 adaptor–like protein (Mal)/TIRAP,
and TLR4 but not with TLR3. These studies suggest that TRIF and TRAM both function in
LPS-TLR4 signaling to regulate the MyD88-independent pathway during the innate immune
response to LPS.
Key words: innate immunity • endotoxin • interferon • signal transduction • host defense
 
Introduction
 
The Toll-like receptor (TLR) family is the essential recog-
nition and signaling component of mammalian host defense
(1–3). At least 10 TLRs have been cloned in mammals,
which recognize molecular products derived from all the
major classes of pathogens. (1–3). Toll signaling to NF-
 
 
 
B
originates from the conserved Toll–IL-1–resistance (TIR)
domain, which mediates recruitment of the TIR domain–
containing adaptor molecule, myeloid differentiation factor
88 (MyD88 [4]), a critical adaptor molecule used by all
TLRs (5). The recruitment of MyD88 to proximal TIR
domains of activated TLRs allows for the interaction and
activation of the IL-1R–associated kinase (IRAK) family
members (6, 7) and the subsequent activation of TNF
receptor–associated factor (TRAF)-6 (8). These events, at
a minimum, result in NF-
 
 
 
B activation via the I
 
 
 
B kinase
(IKK)
 
     
 
 complex (9).
Whereas most of the TLRs seem to be absolutely depen-
dent on the expression of MyD88 for all of their functions,
TLR3 and TLR4 are unique in their ability to activate
both MyD88-dependent and MyD88-independent responses
(10–13). A feature of MyD88-independent signaling is the
induction of a DC maturation pathway and the induction
of the type 1 interferon (IFN-
 
 
 
) (12–16). The transcription
enhancer of the 
 
IFN-
 
 
 
 promoter binds NF-
 
 
 
B, interferon
regulatory factor (IRF)-3, and ATF-2–c-Jun. Whereas all
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TLRs activate NF-
 
 
 
B and ATF2–c-Jun, not all TLRs
induce IFN-
 
  
 
because not all TLRs induce IRF-3 acti-
vation. Thus, TLR3 and TLR4 appear to have evolu-
tionarily diverged from other TLRs to activate gene ex-
pression programs and trigger antiviral responses by a
mechanism involving the coordinate activation of NF-
 
 
 
B
and IRF-3 (17).
MyD88 adaptor–like protein (Mal) (18), also called
TIRAP (19), is a related MyD88-like protein, which was
discovered based on its ability to mediate TLR4 signaling.
Mal/TIRAP has been implicated in LPS-induced IFN-
 
 
 
induction in vitro (12, 20). However, studies with Mal/
TIRAP gene–targeted mice show that Mal/TIRAP func-
tions in the MyD88-dependent NF-
 
 
 
B activation path-
way after LPS stimulation, and engagement of TLR2 by its
ligands (21, 22). A third adaptor protein, TIR domain–con-
taining adaptor–inducing IFN-
 
 
 
 (TRIF) (16), also known
as TIR-containing adaptor molecule (TICAM)-1 (13), in-
teracts with TLR3 and mediates the TLR3-dependent in-
duction of IFN-
 
 
 
 via NF-
 
 
 
B and IRF-3 activation.
Constitutively expressed IRF-3 has been implicated in
the induction of IFN-
 
 
 
 (23–25), RANTES (26, 27), and
ISG-54/56 expression (28). IRF-3 is activated after phos-
phorylation on a cluster of specific COOH-terminal serine
residues (23, 29, 30), facilitating its dimerization and inter-
action with the coactivators CBP and p300 (31–34). The
activated IRF-3 complex then translocates to the nucleus
where it regulates the transcription of target genes (27, 31).
IRF-7 is a related transcriptional regulator that is expressed
mostly in lymphoid cells and is essential for IFN-
 
 
 
 gene
expression (35, 36). The transcription of IRF-7 is induced
by IFN and posttranslationally activated by phosphoryla-
tion on its COOH-terminal serine residues, some of which
are conserved with IRF-3 (35, 37). IKK
 
 
 
 (38, 39) and
TANK-binding kinase (TBK)1 (40–42) are key regulators
of the IRF-3 and IRF-7 activation pathways in cells that
have been exposed to some viruses and/or activated by
dsRNA via TLR3 (43, 44). IKK
 
 
 
 and TBK1 are also re-
quired components of the TRIF signaling pathway, result-
ing in IRF-3 activation (43).
Studies with IRF3-deficient mice have established an es-
sential role for IRF-3 in LPS-induced IFN-
 
 
 
 gene expres-
sion and endotoxin shock (45). However, the molecular
mechanisms regulating the MyD88-independent LPS–
TLR4 pathway to IRF-3 and NF-
 
 
 
B activation are un-
known. Here, we have identified a fourth TIR domain–
containing adaptor molecule, which we have named
TRIF-related adaptor molecule (TRAM). TRAM, like all
of the TIR domain–containing adaptor molecules, acti-
vates NF-
 
 
 
B. In addition, TRAM, like TRIF, activates
IRF-3 and IRF-7. Unlike any of the other known TIR
domain–containing adapters, TRAM appears to be re-
stricted to the LPS activation (TLR4) pathway, whereas
TRIF plays a role in both TLR3 and TLR4 pathways lead-
ing to IRF target gene expression. Our findings suggest
that TRAM may have evolved to mediate TLR4-specific
signals, resulting in a gene expression profile that is not
shared by TLR3.
 
Materials and Methods
 
Reagents.
 
The IRF-3–
 
 
 
N, Gal4–IRF-3, and Gal4–luciferase
reporter gene were from T. Fujita (The Tokyo Metropolitan In-
stitute of Medical Science, Tokyo, Japan). IKK
 
 
 
–k38a and
TBK1–k38a were as described (38, 43). IRF-7, IRF-7–
 
 
 
N, and
Gal4–IRF-7 were from P. Pitha (Johns Hopkins University, Bal-
timore, MD). The 
 
RANTES 
 
reporter construct was as described
(26). The 
 
 
 
 interferon–inducible protein 10 (IP-10) reporter con-
struct was from A. Luster (Massachusetts General Hospital, Bos-
ton, MA). The 
 
NF-
 
 
 
B
 
–luciferase construct (18), pEF-Bos-Flag
Mal, and Flag-TRIF were as described (43). The plasmids pEF-
Bos-Flag-TRAM, TRAM-CFP, TRIF-CFP, and Mal-CFP
were generated by PCR cloning from a human PBMC cDNA li-
brary. pEF-Bos-TRAM-TIR (aa 63–235), pEF-Bos-TRAM-
C113H, TRAM-P112H, and TRIF-P434H were generated us-
ing the Quick Change site-directed mutagenesis kit (Stratagene).
Polyclonal antibodies to IRF-3 were from Zymed Laboratories,
and CBP were from Santa Cruz Biotechnology, Inc. pCMV-
TRIF
 
 
 
N
 
 
 
C and MyD88-deficient mice were gifts from S. Akira
(Osaka University, Osaka, Japan); the MyD88 knockout mice
used were backbred onto a C57BL6 background for five genera-
tions. LPS-derived from 
 
Escherichia coli
 
 strain 011:B4 was pur-
chased from Sigma-Aldrich, dissolved in deoxycholate, and reex-
tracted by phenolchloroform as described (46). Poly IC was from
Amersham Biosciences.
 
Stable Cell Lines.
 
We engineered clonal stable cell lines by
transfecting HEK293 cells with chimeric fluorescent protein
TLR constructs as described (47). A HEK293 cell line stably ex-
pressing both TLR4 and MD-2 was generated by retroviral trans-
duction of HEK-TLR4 cells with a retrovirus encoding human
MD2 (48). HEK-TLR3, HEK–IRF-3–GFP (43), and U373–
CD14 cells (49) were as described.
 
Electrophoretic Mobility Shift Assays.
 
BM-derived macro-
phages were cultured from C57Bl6 mice or age- and sex-
matched MyD88
 
 
 
/
 
 
 
 mice for 8 d in M-CSF (10 ng/ml). Nuclear
extracts from 5 
 
 
 
 10
 
5 
 
cells were purified after LPS (10 ng/ml),
Malp-2 (1 nM), or Poly I:C (50 
 
 
 
g/ml) stimulation for the times
indicated. The extracts were incubated with a specific probe for
the interferon-stimulated response element (ISRE) consensus se-
quence (Promega), electrophoresed, and visualized by autora-
diography (50). Supershift analysis was performed with antibodies
to mouse IRF-3, p65, or IgG control.
 
ELISA.
 
Macrophages (5 
 
 
 
 10
 
4
 
 cells per well) were seeded
into 96-well plates for 24 h before stimulation with LPS, poly IC,
or medium for 12 h. Cell culture supernatants were removed and
analyzed for the presence of RANTES, IP-10, or TNF
 
 
 
 by
ELISA (R&D Systems).
 
Transfection Assays.
 
Cells were seeded into 96-well plates at a
density of 1.5 
 
 
 
 10
 
4
 
 cells per well and transfected 24 h later with
40 ng of the indicated luciferase reporter genes using Genejuice
(Novagen). The thymidine kinase 
 
Renilla-
 
luciferase reporter
gene (Promega) (40 ng/well) was cotransfected in order that the
data could be normalized for transfection efficiency. Cell lysates
were prepared, and reporter gene activity was measured using
the Dual Luciferase Assay System (Promega). Data are expressed
as the mean relative stimulation 
 
 
 
 SD. All of the experiments
described were performed a minimum of three occasions and
gave similar results.
 
Immunofluorescense and Confocal Microscopy.
 
A HEK293–IRF–
GFP stable cell line was transiently transfected with Flag-tagged
constructs as indicated. After allowing 2 d for protein expression
to occur, the transfected cells were fixed, permeabilized, and
stained with Cy3-conjugated anti-Flag antibody (clone M2;T
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Sigma-Aldrich). DRAQ5 was added to counter stain nuclei. Cells
were imaged by confocal microscopy using a Leica TCS SP2
AOBS microscope.
 
RNA Interference.
 
siRNA duplexes targeting the coding re-
gion of TRAM and lamin A/C were from Dharmacon: TRAM-
siRNA sequences, GGAAGAAAGTCGTGGATT (product no
D-004334–01™) and lamin A/C, CTGGACTTCCAGAA-
GAACA. siRNA duplexes targeting the 3
 
 
 
 UTR of TRIF were
as described (13). To determine the efficiency of gene silencing,
293T cells (24 well plates, 4 
 
 
 
 10
 
4
 
 cells/well) were transfected
with 0.5 
 
 
 
g of plasmids encoding TRAM–CFP, TRIF–CFP, or
Mal–CFP expression vectors. These cells were cotransfected
with TRAM or lamin A/C siRNA duplexes (50 nM) using Mi-
rus TransIT
 
®
 
 TKO and TransIT-LT1
 
®
 
 transfection reagents in a
combination protocol exactly according to the manufacturers
recommendations (Mirus). CFP fluorescence was quantified by
flow cytometry (LSR; Becton Dickinson) 24 h later. For re-
porter assays, U373–CD14 cells or TLR3–expressing HEK293
cells (4 
 
 
 
 10
 
4
 
 cells/well) were transfected with 0.5 
 
 
 
g of the
RANTES reporter gene and 0.25 
 
 
 
g of a thymidine kinase–
renilla reporter gene and cotransfected with 50 nM of siRNA
targeting vectors as described above in 24-well tissue culture
 
dishes. 36 h after transfection, cells were stimulated with LPS or
dsRNA for 
 
 
 
8 h before luciferase activity was measured.
 
Coimmunoprecipitation.
 
293T cells or TLR-expressing cells
(10 cm plates) were transfected using GeneJuice (Novagen) with
4 
 
 
 
g of the indicated plasmids. Cells were lysed in 1 ml of lysis
buffer (20 mM Tris-HCl, 2 mM EDTA, 137 mM NaCl, 0.5%
Triton X-100, glycerol 10%, with protease inhibitors) 1-2 d after
transfection. Polyclonal anti-GFP (Molecular Probes), anti–IRF-3,
or anti-CBP antibodies were incubated with the cell lysates in
protein A sepharose overnight. The immune complexes were
precipitated and subjected to 4–15% SDS-PAGE and immuno-
blotted for Flag- or CFP/YFP-tagged adapters using the anti-Flag
mAb M2 (Sigma-Aldrich) or anti-GFP mAb (CLONTECH Lab-
oratories), which also recognizes the spectral variants of GFP.
 
Results
 
LPS and dsRNA Activate IRF-3 and IRF-7.
 
The pro-
moters of RANTES and IP-10, like that of IFN-
 
 
 
, con-
tains transcription factor binding elements for NF-
 
 
 
B and
IRF-3 (26, 27). The expression of RANTES and IP-10
represent downstream targets of Toll receptors that are en-
Figure 1. LPS and dsRNA activate IRF-3
and IRF-7. (a) BM-derived macrophages
from WT and MyD88-deficient mice were
stimulated with LPS (0.1–100 ng/ml),
Malp-2 (5 nM), and dsRNA (1–100  g/ml)
for 12 h. The concentration of RANTES
was measured by ELISA. (b) Nuclear extracts
were isolated from WT and MyD88-deficient
macrophages stimulated with LPS (10 ng/ml),
Malp-2 (5 nM), and dsRNA (50  g/ml) for
1 h and subjected to EMSA using a 32P-
labeled ISRE consensus sequence (ISG-15)
as a probe. Activated complexes were visu-
alized by autoradiography. Activated ISRE
DNA-binding complexes were preincubated
with polyclonal antibody to IRF-3 or two
control antibodies before incubation with
the ISRE probe (right). (c) TLR3 and
TLR4/MD2-expressing HEK293 cell lines
were transfected with a luciferase reporter
gene containing the Gal4 upstream activation
sequence and with Gal4-DBD, Gal4–IRF-3,
or  Gal4–IRF-7 (40 ng). After 24 h, cells
were stimulated with LPS (10 ng/ml),
dsRNA (50  g poly IC/ml), IL-1  (10
ng/ml), or left untreated for  8 h, and lu-
ciferase reporter gene activity was measured.T
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tirely independent of MyD88 expression after stimulation
by LPS or dsRNA. Stimulation of mouse BM-derived
macrophages with LPS (TLR4) or dsRNA (TLR3) in-
duced RANTES secretion, an effect that was observed
equally in BM macrophages deficient in MyD88 (Fig. 1 a).
This was also true for IP-10 levels as measured by ELISA
(unpublished data). In contrast, TLR2 signaling via li-
popeptides absolutely requires MyD88 and does not lead
to RANTES expression. TLR2-mediated production of
TNF
 
 
 
 was entirely absent in MyD88-deficient macro-
phages (unpublished data), in agreement with published
studies (11, 51, 52).
We next examined the effect of LPS and dsRNA on
IRF-3 DNA binding activity. IRF-3 DNA binding activity
was induced in both WT and MyD88-deficient macro-
phages after LPS and dsRNA stimulation (Fig. 1 b). The
presence of IRF-3 in this ISRE DNA binding complex
was confirmed by depletion (“gel shift”) analysis using anti-
bodies to IRF-3 (Fig. 1 b, bottom). Stimulation of cells
with the TLR2 ligand, Malp-2, did not result in IRF-3 ac-
tivation. NF-
 
 
 
B was activated in WT cells by all stimuli
and in MyD88-deficient macrophages after LPS or dsRNA
stimulation (unpublished data).
We next addressed the question of whether the related
transcriptional regulator IRF-7 was a target of TLR sig-
naling. We employed an in vivo assay for IRF-7 activa-
tion, which utilizes a hybrid protein consisting of the
yeast 
 
Gal4
 
 DNA-binding domain (DBD) fused to 
 
IRF-7
Figure 2. TRAM activates IRF-3 and IRF-7. (a) Alignment of TIR domains of TRAM, TRIF, MyD88, and Mal with TLR1, TLR2, TLR3, and
TLR4. The amino acid colors are based on their physico-chemical properties where yellow   small, green   hydrophobic, turquoise   aromatic,
blue   positively charged, and red   negatively charged. (b) HEK293 cells were transfected as in Fig. 1 c and cotransfected with 40 ng of TRAM or
TRIF. After 24 h, luciferase reporter gene activity was measured.T
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lacking its own DBD (53). Reporter gene expression
from the Gal4 upstream activation sequence in this assay
requires IRF-7 activation (31). IRF-3 activation was
also measured in this assay using a Gal4–IRF-3 fusion
protein. Stimulation of TLR3 or TLR4/MD2-expressing
HEK293 cells with dsRNA or LPS but not IL1  activated
both IRF-3 and IRF-7 (Fig. 1 c). IRF7 plays a critical
role in regulating IFN- 1 expression. Exogenously ex-
pressed IRF7 increased the activation of an IFN- 1 re-
porter construct when TLR4/MD2- or TLR3-expressing
Figure 3. TRAM interacts
with IRF-3 and CBP and signals
via IKK  and TBK1. (a) IRF-3–
GFP–expressing HEK293 cells
were plated on 35-mm glass-
bottom sterile tissue culture
dishes and transiently trans-
fected with 1  g of Flag-tagged
TRAM, TRIF, or pCDNA3.1
and visualized 24 h later by con-
focal microscopy. (b) 293T cells
were transfected with 4  g of
Flag-TRAM with or without a
plasmid encoding IRF-3 (un-
tagged) as indicated. 24 h later,
whole cell lysates were immuno-
precipitated with anti–IRF-3,
anti-Flag, or anti-CBP, and the
immunoprecipitated complexes
were immunoblotted for Flag-
tagged TRAM and IRF-3.
Whole cell lysates (WCL) were
also analyzed for Flag-tagged
proteins. (c) HEK293 cells were
transfected with the RANTES
luciferase reporter gene and
TRAM (20 ng) and cotrans-
fected with increasing concentra-
tions of IKK -k38a, TBK1-k38a,
or IRF3- N from 10, 20, 30,
40, 60, and 80 ng. Luciferase
reporter gene activity was mea-
sured 24 h after transfection.T
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HEK293 cells were stimulated with LPS or dsRNA,
whereas a dominant negative IRF7 mutant inhibited the
effect (unpublished data). These observations are strong
evidence that TLR3 and TLR4 activate IRF-3 and
IRF-7 and, as a result, induce IRF target genes such as
RANTES and IFN / .
Discovery of a Fourth TIR Domain–containing Adaptor Mole-
cule, TRAM. A search of the human genome for addi-
tional TIR domain–containing adaptor molecules resulted
in the identification of a small protein fragment that shares
sequence similarity with other TIR domain–containing pro-
teins, most notably with TRIF/TICAM-1. A set of overlap-
ping EST sequences were subsequently identified and used
to clone the full-length cDNA of human and mouse
TRAM, which share 75% sequence identity (sequence data
available from GenBank/EMBL/DDBJ under accession nos.
AY232653 and AY268050, respectively). The TRAM gene
is located on human chromosome 5 (ENSEMBL ID:
ENSG00000164226). TRAM is a 235 aa protein with a
COOH-terminal TIR domain. Fig. 2 a shows a multiple se-
quence alignment of human and mouse TRAM with other
human adapters and TLRs. The crystal structure of the TIR
domain of TLR2 has been resolved. The TIR domain “BB
loop” is an essential part of its structure, and this portion of
the molecule appears to engage downstream elements such
as adaptor molecules or other TLRs (3, 54). Most TIR do-
main BB loop sequences contain a conserved proline residue
in the BB loop. When this residue is mutated to histidine,
the mutant protein is typically unable to signal and may even
function as a dominant suppressing mutation (18, 19, 55).
Unlike the other known adaptor proteins, both human and
mouse TRAM contain a cysteine residue at this position
(Fig. 2 a, #). A proline residue resides directly adjacent to
this residue in TRAM, at position 112.
Figure 4. TRAM mediates the TLR4 pathway
to IRF-3 and IRF-7. (a) HEK293 cells were trans-
fected with 40 ng of a RANTES reporter construct
and cotransfected with TRAM, TRAM-TIR,
TRAM-C113H, or TRAM-P112H. (b) TLR4/
MD2- and TLR3-expressing HEK293 cell lines
were transfected with a luciferase reporter gene
containing the Gal4 upstream activation sequence
and cotransfected with Gal4–DBD, Gal4–IRF-3,
or Gal4–IRF-7 or the RANTES luciferase reporter
gene as well as TRAM-C113H or TRIF- N C.
The next day, cells were stimulated with LPS (10
ng/ml) or dsRNA (50  g/ml poly IC) or left un-
treated for  8 h, and luciferase reporter gene activity
was measured.T
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Because of the similarity in the sequence of the TIR do-
main of TRAM and TRIF, we first compared the effect of
TRIF and TRAM on IRF-3 and IRF-7 activation. Over-
expression of TRAM activated the IRF-3 and IRF-7 re-
sponse (Fig. 2 b). TRIF also activated both transcription
factors (Fig. 2 b). As a consequence, TRAM and TRIF also
induced the IFN- , RANTES, IP-10, and IFN- 1/ 2
promoters, all of which contain ISRE elements (unpub-
lished data). These data imply that TRAM and TRIF also
activate NF- B, as some of these promoters (IFN- ,
RANTES, and IP-10) also require NF- B for full activity
(see TRAM Also Activates NF-kB).
As a further test of TRAM- and TRIF-dependent
IRF-3 activation, we examined their effects on the nuclear
translocation of IRF-3. Overexpression of TRAM and
TRIF in a stable cell line expressing a GFP chimera of
IRF-3 resulted in the nuclear translocation of this IRF-3–
GFP fusion protein (Fig. 3 a). TRIF has been shown re-
cently to coimmunoprecipitate with IRF-3 (16). We were
interested in determining if TRAM might also associate
with IRF-3. When HEK293 cells were transfected with
Flag-tagged TRAM and immunoprecipitated with anti-
body to endogenous IRF-3, Flag-tagged TRAM could be
detected in the immunoprecipitated complex (Fig. 3 b,
top). Immunoprecipitation with an anti-Flag antibody con-
firmed this interaction; endogenous and cotransfected IRF-3
could be detected in the immunoprecipitated complexes
(Fig. 3 b, second panel). TRIF also interacted with endog-
enous and transfected IRF-3 in agreement with published
studies (unpublished data). There were no nonspecific asso-
ciations detected in cells lacking the transfected adaptor
constructs. Although not shown, we also performed similar
experiments with IRF-7. IRF-7 also interacted with
TRAM and TRIF and vice versa.
Activated IRF-3 must associate with the coactivators
CBP and p300 in order to enhance target gene expression
(31–34). When endogenous CBP was immunoprecipitated
from cell lysates expressing transfected Flag-tagged TRAM,
TRAM could be detected in these immunoprecipitated
complexes (Fig. 3 b, third panel). This was also true for
transfected TRIF (unpublished data).
The noncanonical I B kinases, IKK  (38, 39) and
TBK1 (40–42), are key regulators of the IRF3 activation
pathway resulting from viral exposure and activation of
TLR3 or TRIF-signaling cascades (43, 44). IKK  has also
been implicated in LPS signaling (56). We next examined
the effect of dominant negative mutants of IKK  and
TBK1 on TRAM signaling. We used the RANTES re-
porter gene construct to address this issue. Cells were
cotransfected with TRAM, which activates downstream
molecules as a result of overexpression, and the kinase in-
active mutants of IKK  (IKK -k38a) or TBK1 (TBK1-
k38a). Both mutants inhibited TRAM-induced RANTES
reporter activation in a dose-dependent manner, suggest-
ing that these two kinases may also function downstream
of TRAM. Together these observations provide strong
evidence that TRAM and TRIF are important compo-
nents of the IRF3 signaling pathway and suggest that these
adaptor proteins form a multiprotein complex with IRF-
3/7, CBP, and the IRF-3/7 kinases (IKK  and TBK1)
during signal transduction.
TRAM Activates the IRF Pathway in the TLR4 but Not the
TLR3 Signaling Pathway. We next generated a series of
TRAM mutants and examined their ability to activate the
RANTES reporter gene. Transfection of HEK293 cells
with a plasmid encoding the TIR domain alone of TRAM
(TRAM-TIR) induced the RANTES reporter, although
this response was considerably less than that observed with
the full-length TRAM cDNA (Fig. 4 a). TRAM contains
a cysteine residue (C113) in the BB loop with an adjacent
proline residue (P112). Mutation of the proline residue
to histidine (TRAM-P112H) significantly impaired the
RANTES-inducing activity of TRAM, whereas mutation
of the cysteine residue at position 113 (TRAM-C113H)
completely abrogated all activity (Fig. 4 a). This suggested
that either TRAM-C113H or TRAM-P112H might
function as a dominant interfering mutant of TRAM activ-
ity. The effect of these TRAM constructs was similar when
an IP-10 promoter–based reporter construct was assessed
(unpublished data).
We subsequently examined the effect of these TRAM
mutants on TLR-mediated signaling that culminates in
RANTES promoter activation or the activation of the
transcription factors IRF-3 and IRF-7. We focused on
TLR3 and TLR4 because of their unique abilities to acti-
vate both NF- B and IRF-3. Neither the TRAM-TIR
domain nor the TRAM-P112H mutants had any domi-
nant negative inhibitory activity on either TLR-depen-
dent IRF-3 pathway tested (unpublished data). Transfec-
tion of HEK-TLR3 cells with TRAM-C113H had no
inhibitory effect on dsRNA-induced RANTES response
(Fig. 4 b). In contrast, LPS-induced activation of the
RANTES reporter via TLR4 was impaired by the
TRAM-C113H mutant (Fig. 4 b, left). The LPS-depen-
dent induction of the RANTES reporter gene was consid-
erably less potent than that observed after TLR3 stimula-
tion. The TRAM-C113H mutant also inhibited the
TLR4- but not the TLR3-dependent activation of IRF-3
and IRF-7 (Fig. 4 c). The TRAM-C113H mutant also in-
hibited the TLR4- but not the TLR3-dependent activa-
tion of an IP-10 reporter construct (unpublished data). We
also examined the role of TRIF in the TLR3- and TLR4-
dependent pathways in parallel by expressing a dominant
negative mutant of TRIF lacking both the NH2-terminal
and COOH-terminal regions surrounding the TIR do-
main (TRIF N C) [16]). As expected, this mutant com-
pletely suppressed the TLR3-dependent response (Fig.
4 b). The TRIF N C mutant also inhibited the TLR4
response, although the effect was less potent than that ob-
served in the TLR3 pathway under identical experimental
conditions (Fig. 4 d, right). Together, these observations
suggest that TRIF regulates the TLR3 and TLR4 path-
ways to IRF target genes, whereas TRAM appears to be
TLR4 specific.
TRAM Also Activates NF- B. We subsequently ad-
dressed the role of TRAM in the NF- B activation path-T
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way. Transfection of HEK293 cells with TRAM resulted
in a potent NF- B activation response (Fig. 5 a). The iso-
lated TIR domain of TRAM also induced a robust NF- B
response, though this was considerably less than that ob-
served with the full-length gene (Fig. 5 a). Neither the
TRAM-P112H nor the TRAM-C113H mutants induced
NF- B activation. Thus, like all of the other known adapt-
ers, TRAM is also an NF- B activator.
The TRAM-C113H–negative interfering mutant was
next tested for its ability to inhibit TLR-dependent signal-
ing to NF- B. TLR2-, TLR3-, TLR4/MD2-, TLR7-,
and TLR8-expressing HEK293 cells were transfected indi-
vidually with an NF- B reporter gene and cotransfected
with increasing concentrations of TRAM-C113H. After
stimulation with their cognate TLR agonists, luciferase re-
porter gene activity was measured. NF- B activation in-
duced by the TLR2 agonist Malp-2, the TLR3 agonist
dsRNA, the TLR7 and TLR8 agonists, R-848, IL-1 , or
TNF  were all unaffected when cells were cotransfected
with the suppressing TRAM-C113H mutant (Fig. 5 b). In
striking contrast to these negative results, the TRAM-
C113H mutant inhibited LPS-induced NF- B activity in
HEK–TLR4–MD2 cells. The TRAM-P112H had no in-
hibitory activity on any TLR pathway to NF- B, includ-
ing the TLR4 pathway, confirming the importance of the
C113 residue for this response. These observations suggest
that TRAM regulates NF- B and IRF-3/7 in the LPS/
TLR4 signaling pathway.
TRIF and TRAM Cooperate in the IRF-3 Activation Path-
way. We examined the effect of the TRIF N C mutant
on TRAM-induced RANTES promoter activation in or-
der to define the relationship between TRIF, TRAM, and
the TLR4 pathway. The TRIF N C construct inhibited
the TRIF-induced RANTES reporter gene response (Fig.
6 a, hatched bars). The TRIF N C mutant completely
abrogated the TRAM-induced RANTES reporter gene
response (Fig. 6 a). The TRAM-C113H mutant also abro-
gated the induction of the RANTES reporter gene in re-
sponse to TRAM overexpression (Fig. 6 a, far right) but
had no effect on the response to TRIF overexpression (Fig.
6 a, hatched bars). The observation that a TRIF dominant
negative construct blocked TRAM activity but not vice
versa suggests that TRAM signaling requires TRIF.
Subsequently, we performed coimmunoprecipitation ex-
periments on cells that heterologously expressed both of
these gene products and the related adaptor molecule Mal/
Figure 5. TRAM activates NF- B and is spe-
cific to the TLR4 pathway. (a) HEK293 cells
were transfected with 40 ng of an NF- B re-
porter construct and cotransfected with TRAM,
TRAM-TIR, TRAM-C113H, and TRAM-
P112H. (b) TLR-expressing HEK293 stable cell
lines were transfected with 40 ng of an NF- B
reporter gene and cotransfected with increasing
concentrations of TRAM-C113H. 1 d after trans-
fection, TLR-expressing cells were stimulated
with Malp-2 (2 nM), dsRNA (100  g/ml poly
IC), LPS (10 ng/ml), R-848 (10  M), IL1  (10
ng/ml) or TNF  (10 ng/ml) or left untreated or 8 h,
and luciferase reporter gene activity was measured.T
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TIRAP. These immunoprecipitation studies demonstrated
that TRAM interacted with both TRIF and Mal/TIRAP
(Fig. 6 b, left). TRIF also interacted with Mal (Fig. 6 b,
right). Finally, both TRIF and TRAM interacted with the
Mal-P125H (dominant negative) mutant. The stronger in-
teraction of TRIF and TRAM observed with the Mal-
P125H mutant does not reflect a higher avidity for this
interaction but rather was a consequence of the higher ex-
pression level of the MAL-P125H mutant in whole cell ly-
sates, compared with the expression level of Mal or TRIF
(Fig. 6 b, middle). These data may explain a previously un-
explained finding, i.e., that the Mal/TIRAP dominant
negative mutant powerfully inhibited LPS-induced signal-
ing to NF- B (18, 19) and IFN-  expression (12, 20),
whereas the Mal/TIRAP knockout mouse both retained
the ability to induce NF- B (21, 22) and IFN-  expression
(22). It is likely that the more profound effect of the domi-
nant negative construct is due to its ability to limit the
function of other adaptor molecules involved in LPS sig-
naling such as TRAM and TRIF. Furthermore, these data
suggest that TRIF and TRAM interact with Mal at a site
distinct from the TLR4 interaction site of Mal (19).
Coimmunoprecipitation studies were next performed to
determine if TRAM interacts with TLR4. Stable TLR3-
or TLR4-expressing cell lines were transiently transfected
with Flag-tagged expression vectors for TRAM, TRAM-
C113H, and Mal, and coimmunoprecipitation experiments
were performed. These experiments indicated that TRAM
interacts with TLR4 but not with TLR3 (Fig. 6 c), one
more indication of the specificity of TRAM for the TLR4
pathway. The dominant negative mutant TRAM-C113H
failed to immunoprecipitate with TLR4, suggesting that
the C113 residue is critical for this interaction. Mal also in-
teracted with TLR4 and not TLR3, providing additional
evidence that Mal has a role in the TLR4 but not the
TLR3 signaling pathway.
TRIF and TRAM Are Essential for TLR4 Signaling.
The data obtained by testing dominant negative constructs
and assessing protein–protein interactions suggest that TRIF
and TRAM both function in the TLR4 signal transduc-
tion pathway. Dominant negative constructs, when highly
expressed, have the potential to bind (as seen in Fig. 6 b)
and interfere with proteins that might otherwise not be re-
lated to a specific signal transduction pathway. Therefore,
we performed siRNA-silencing experiments as an addi-
tional methodology to delineate the relationship between
TRIF and TRAM in the TLR4 and TLR3 signaling path-
ways.
To assess the gene-silencing activity of siRNA duplexes
we selected, cells were transiently transfected with a fluo-
rescent chimeric construct of TRAM (TRAM–CFP) and
cotransfected with siRNA duplexes targeting the coding
region of TRAM or a control siRNA, lamin A/C. These
siRNA duplexes can therefore be used to assess the silenc-
ing effect of a fluorescent chimeric construct of TRAM.
This methodology has been used extensively to assess
siRNA efficiency and provides a quantitative assessment of
silencing efficiency (57). We found that siRNA duplexes
Figure 6. TRAM signaling requires the expression of TRIF. (a) HEK293
cells were transfected with the RANTES luciferase reporter gene, TRAM
or TRIF (40 ng), and cotransfected with TRIF- N C or TRAM-C113H.
Luciferase reporter gene activity was measured 24 h later. (b) 293T cells
were transfected with 4  g of TRAM-CFP or TRIF-CFP and cotrans-
fected with Flag-Mal, Flag-Mal-P125H, or Flag-TRIF. Whole cell lysates
were harvested 48 h later and immunoprecipitated with anti-GFP antibody
(which also immunoprecipitates cyan fluorescent protein [CFP] or yellow
fluorescent protein [YFP]). Immunoprecipitated complexes were resolved
by SDS-PAGE and immunoblotted for Flag-tagged adapters. Whole cell
lysates (WCL) were also analyzed for CFP- and Flag-tagged proteins by
immunoblotting. (c) Stable TLR4YFP- or TLR3YFP-expressing HELA cells
were transfected with 4  g of plasmid encoding Flag-Mal, Flag-TRAM, or
Flag TRAM-C113H. 48 h later, whole cell lysates were immunoprecipi-
tated with anti-GFP antibody, and immunoprecipitated complexes were
immunoblotted for Flag-tagged adapters. Western blotting of lysates demon-
strates expression of stable TLRs and transfected adaptor proteins.T
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targeting the TRAM coding region completely ablated the
expression of the TRAM–CFP chimeric fusion protein,
whereas lamin A/C siRNA duplexes were without effect
(Fig. 6 a). We also examined the effect of these TRAM
siRNA duplexes on TRIF and Mal expression in order to
ensure the specificity of the TRAM siRNA duplexes. This
is particularly important as TRIF and TRAM are most
closely related in sequence. TRAM siRNA duplexes had
no effect on chimeric constructs of TRIF or Mal expressed
as CFP fusion proteins (Fig. 7 a).
Having determined that the siRNA duplexes chosen for
TRAM effectively and specifically suppressed TRAM ex-
pression, we examined the effect of these siRNA duplexes
on the LPS and dsRNA signaling pathways. Native macro-
phages and macrophage cells lines are extraordinarily diffi-
cult to transfect with siRNA. In contrast, U373–CD14
cells resemble CNS macrophages, are easily transfectable,
and are highly inducible by treatment with LPS. Thus, we
tested the effect of TRAM siRNA duplexes on the LPS re-
sponse in U373–CD14 cells. In comparison, we used
HEK-TLR3 cells to test the effects of TRAM and TRIF in
pIC-stimulated RANTES expression. The response of
each of these cell lines to these TLR ligands is comparable.
TRAM siRNA duplexes inhibited the LPS-dependent
induction of the RANTES reporter gene in U373–CD14
cells, whereas siRNA targeting of lamin A/C had no effect
(Fig. 7 b, top). We also examined the effect of published
TRIF siRNA duplexes, which target the 3  untranslated
region of TRIF on this response. These TRIF siRNA du-
plexes have been shown to completely silence endogenous
TRIF mRNA expression (13). TRIF siRNA duplexes
also inhibited the LPS response to RANTES induction
(Fig. 7 b, top). In striking contrast to LPS, when the
TLR3-mediated response to dsRNA was analyzed, the
TRAM siRNA duplexes had no inhibitory effect on
the dsRNA response, whereas TRIF siRNA duplexes in-
hibited dsRNA-dependent RANTES induction, in agree-
ment with published reports (13). As with RANTES,
siRNA silencing of TRAM prevented LPS but not poly
IC induction of the IP-10 promoter (unpublished data).
These observations confirm the studies with TRIF and
TRAM dominant negative mutants and demonstrate that
both adaptor molecules are required for full LPS-TLR4
signaling to IRF target genes.
Discussion
The ability of individual TLRs to discriminate between
invading pathogens is an important determinant of the
unique gene expression profiles activated by different mi-
croorganisms. Whereas the specificity of microbe detec-
tion begins with the ligand recognition features of one or
more TLR, the discovery of a family of TIR domain–con-
taining adaptor molecules, including MyD88 (4), Mal (18,
19), TRIF (13, 16), and TRAM, suggest that the outcome
of induced pathogen recognition also depends on the
TLR-restricted utilization of these molecules, alone and in
combination, to drive a stimulus-specific response. The
TLR3- and TLR4-restricted utilization of IRF-inducing
adaptor molecules such as TRAM and TRIF induces not
only the cytokines, costimulatory molecules, and antimi-
crobial peptides that are induced by all TLRs but also
anti–viral type I interferons and specific chemokines in-
cluding IP-10 and RANTES.
The dominant negative, siRNA, and protein–protein
interaction data presented here demonstrate that TRAM is
specifically required for LPS signaling, whereas TRIF is
required for signaling by both TLR3 and TLR4. Both
MyD88 and Mal/TIRAP also have a role in more than
one TLR. Thus, the activity of TRAM, unlike any of the
other known adaptor molecules, may be restricted to a
single TLR.
Defining the constituents of the TLR4 pathway acti-
vated by LPS has proven to be a complicated process.
First, it was believed that MyD88 was the only adaptor
molecule needed for the full extent of the LPS response
(11). However, data rapidly emerged that showed that at
least part of the LPS response also involves Mal/TIRAP
(21, 22). Thus, both MyD88 and Mal/TIRAP are in-
volved in LPS signal transduction but cannot account for
all, or even most, of the observed signaling traffic. The ex-
istence of TRAM and the potential cooperativity of
TRAM and TRIF in the TLR4 pathway may explain
how double MyD88–Mal-null cells are still capable of re-
Figure 7. TRAM and TRIF are required for RANTES activation by
LPS. (a) 293T cells plated in 24-well plates were transfected with 1  g of
plasmids encoding TRAM-CFP, TRIF-CFP, or Mal-CFP and cotrans-
fected with 50 nM siRNA-TRAM or lamin A/C as indicated. 24 h later,
CFP fluorescence was measured by flow cytometry using a 405 nm laser
for excitation of CFP. The siRNA-TRAM nearly completely abolished
expression of the subpopulation of cells that express CFP. (b) U373–
CD14 or TLR3-expressing HEK293 cells were transfected with a
RANTES reporter gene and cotransfected with siRNA duplexes as indi-
cated for 36 h. Cells were then stimulated for 8 h with LPS or dsRNA,
and luciferase reporter gene activity was measured.T
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sponding to endotoxin. It is intriguing that the TLR4
pathway requires TRIF, TRAM, MyD88, and Mal/
TIRAP, whereas TLR3 signaling appears to require only
TRIF and MyD88. The gene expression profiles activated
after dsRNA and LPS stimulation of cells, though similar,
are not identical (17, 58). The utilization of TRAM by
TLR4 and not TLR3 may allow LPS-TLR4 to induce
signaling pathways and gene expression programs not pos-
sible by TLR3–TRIF-mediated signaling. Thus, the com-
binatorial utilization of TRIF and TRAM by TLR4 may
allow a specific tailoring of the immune response to the
pathogens that activate TLR4.
Both functional and direct biochemical studies indicate
that the adaptor molecules used for the LPS response are
interacting with one another and with TLR4. One obvious
question that needs to be addressed is how these types of
observations, which were made in a few types of trans-
fected cell lines and primary BM-derived macrophages, ap-
ply to the myriad of cell types that respond to LPS. The re-
sponse to LPS is not uniform, an observation that is
generally attributed to the cell surface density of the LPS
receptor components. However, simple receptor density
clearly does not always explain these differences and many
different mechanisms are undoubtedly at work. Based on
scanning electron micrographs of LPS-exposed cells, it is
likely that activated TLR4 forms a large “signalosome” in-
volving multiple molecules of TLR4 (unpublished data).
The cytoplasmic face of the activated LPS receptor is likely
to have a large surface upon which these adaptor molecules
may sit. We propose that cell-specific differences in the re-
sponse to LPS may also involve differences in the number
and the composition of adaptor molecules that assemble on
TLR4. Cocrystalization of the cytoplasmic face of TLRs in
complexes with the various adaptor molecules or combina-
tions of adaptor molecules is going to be necessary to fully
understand the physical basis of how an activated Toll re-
ceptor actually collaborates with these molecules to propa-
gate an intracellular signal. We predict that TRAM will be
a portion of a large platform of adaptor molecules bound to
TLR4 upon which a variety of kinases and other molecules
can effectively function to initiate LPS responses.
While this manuscript was in preparation, Shu and col-
leagues reported on the identification of TRAM, to which
they gave the name TIRP, as an adaptor molecule that in-
teracts with the IL-1R, Mal, IRAK, and TRAF-6 (59).
These authors reported that TRAM/TIRP functions ex-
clusively in IL-1 signaling (59). In agreement with Shu and
colleagues, we have also detected TRAM in association
with Mal (Fig. 4 b), TRAF-6 and the IL1RAcP (unpub-
lished data). Furthermore, we detected no inhibition of the
IL1-induced NF B response when cells were transfected
with the TRAM–C113H mutant (Fig. 6). Since submis-
sion of this paper, two articles have reported on the role of
TRIF in LPS signaling (60, 61). One of these articles (61),
postulates that there may be another TLR4 adaptor mole-
cule, which is designated “X.” TRAM may represent a po-
tential candidate for such a molecule, although the precise
mechanism whereby the four known LPS adapters interact
and contribute to MyD88-dependent and MyD88-inde-
pendent signaling remains to be determined.
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